Project Grant R01AI189603
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501 in funding to the Regents of the University of Minnesota to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB) infection. The award aims to define how CD4 T cell-derived effector functions drive myeloid cell activation and contribute to protective immunity...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- This $854,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to assess post-tuberculosis (TB) lung disease in TB patients with and without HIV coinfection. The project will utilize novel positron emission tomography (PET) imaging techniques, such as 11C-rifampin PET, to longitudinally profile lesional characteristics and antibiotic exposures in animal models...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $1,640,492 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine to study the role of the ESX5 secretome of Mycobacterium tuberculosis in TB and TB-HIV pathogenesis and immunity. The researchers generated a genetic deletion of the ESX5 locus, which they found produced a live attenuated vaccine that is highly effective at preventing TB in...
- This federal Project Grant award of $819,998.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), to The Regents of the University of California, San Francisco. The purpose of the award is to conduct research to understand how Mycobacterium tuberculosis (M. tuberculosis) infection triggers host cell death mechanisms, with the goal of identifying new therapeutic targets to augment protective...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- This Project Grant award of $802,499, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to characterize the genetic factors involved in tuberculosis (TB) susceptibility and their interaction with the immune system. The key objectives are to: 1) generate population-level genetic data on 5,000 case-control samples from diverse South African populations to identify genetic markers associated...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $813,450 to Case Western Reserve University to conduct research evaluating human T cells specific for Mycobacterium tuberculosis (MTB) antigens that are processed and presented by infected macrophages. The objective is to gain insight into which MTB antigens are presented and the composition and kinetics of the T cell repertoire targeting these...
- This $162,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (PDCs) in Mycobacterium tuberculosis (MTB) infection. The research aims to quantify PDC trafficking and activation in the lungs during MTB infection, and determine how PDC-driven type I interferon responses impact MTB control. The project will leverage a mouse model that...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award of $743,817 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to delineate T cell receptor (TCR) families associated with protection from progression to pulmonary tuberculosis (TB) disease. The research will use advanced imaging techniques like fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET-CT) to identify TB-exposed household contacts with adaptive immune control, and then profile the TCRs and transcriptional signatures in their lungs and periphery. The findings will be validated in an independent cohort to evaluate the function of T cells recognizing protection-associated antigens. This work seeks to advance the understanding of correlates of protective immunity against TB, which is crucial for developing an effective vaccine to combat this leading cause of infectious disease mortality worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $743.8k | 8/12/25 |